skip to Main Content

About PILA PHARMA

PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.

PILA PHARMA is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 was in-licensed in 2016 and was prior to that found to be safe in people without diabetes.
The maximal tolerable dose in this population was set to bi-daily doses of 4 mg.

Pila Pharma has conducted 2 clinical trials to investigate the safety of XEN-D0501 in people with type-2 diabetes.
It was found that is safe to administer single doses of 1, 2, 4 and 8 mg XEN-D0501 (PP-CT01, Phase 2a).
Likewise, bi-daily doses of 4 mg for 28 days (PP-CT02, Phase 2a) in people with type 2 diabetes was safe without any SAE’s.

The next milestone will be to investigate the safety and efficacy of XEN-D0501 when dosing for 3 months in people with type 2 diabetes (Phase 2b).
Pila Pharma is currently fundraising for that as well as for a pipeline including an orphan indication.

PilaPharma

Announcement

We recently published some of our early data on the beneficial effect of TRPV1 inhibition on glucose regulation and the association to (neurogenic) inflammation.

Please, find it here

(24-July-2019)

PILA PHARMA AB has been selected to be 1 of 200 SMEs to receive an SME Instrument Phase 1 grant (EUR 50 000).

Read the general EU announcement here and the project abstract here

(21-Dec-2018)

Novo-forsker gjorde ph.d.-projekt til biotekselskab og forbereder nu fase 2-studie.

An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in Danish here

(02-Jan-2019)

Om jag har rätt kan detta bli gigantisk.
An interview with CEO Dorte X. Gram by BioStock, Sweden.

Read the article in Swedish here

(13-Nov-2018)

PILA PHARMA är klar med uppstartsfasen och flyttar ut från inkubatorn.
An interview with CEO Dorte X. Gram published by Medeon, Sweden.

Read the article in Swedish here

(13-Dec-2017)
Pila Pharma

Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.

Check out the resulting article here

(13-Dec-2017)

Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.

Read the article in Swedish here

(03-Jul-2017)

We are proud to be on the cover of the June 2017 issue of Affärslivet Norden, Medicine and Science magazine that focuses on innovation.
The magazine was distributed with Svenska Dagbladet.

Read the article in Swedish here
Read the magazine in Swedish here

(22-Jun-2017)

Stora förhoppningar på nytt effektivt läkemedel mot diabetes typ 2.
An interview with CEO Dorte X. Gram  published in ‘Analys Öresund’, Distributed with Dagens Industri, Sweden.

Read the article in Swedish here
Read the magazine in Swedish here

(15-Jun-2017)

“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by Sydsvenskan, Sweden.

Read the article in Swedish here

(04-Dec-2016)

We are proud to be on the cover of the September 2016 issue of Nordic Life Science Magazine as representatives of Nordic Life Science companies.

Read the article here
Read the magazine here

(09-Sep-2016)
Back To Top
×Close search
Search